Search results
Results from the WOW.Com Content Network
Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...
The prescribing information for Jakafi now includes a new recommended starting dose of 5 mg twice daily of Jakafi for patients with baseline platelet counts between 50-100 x 10 9 /L (50,000 to ...
In this study, where twice as many patients were randomized to Jakafi (146) as to placebo (73), there were 14 percent (n=20) deaths in the group treated with Jakafi and 22 percent (n=16) in the ...
Jakafi is approved in the U.S. for treating acute GvHD and is considered a remedy for certain bone marrow and blood d FDA approves Incyte's treatment for chronic graft-versus-host disease Skip to ...
From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN).
A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, [1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway in lymphocytes.
The beat reflects high demand for Incyte's cancer drug while inventory held by distributors returned to normal from lower than usual levels in the first quarter. Incyte has been diversifying and ...
Mitsubishi Tanabe Pharma Corporation is a Japanese pharmaceuticals company from Osaka, [1] a subsidiary of Mitsubishi Chemical Holdings Corporation. Mitsubishi Pharma Corporation (三菱ウェルファーマ株式会社, Mitsubishi Werufāma Kabushiki-gaisha) was formed in 2001 from the merger of Mitsubishi-Tokyo Pharmaceuticals and Welfide Corporation.